{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:33:49Z","timestamp":1787787229058,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>ALK-positive lung cancers are known to have favorable responses with oral tyrosine kinase inhibitors. Lorlatinib is an approved treatment option post first and second-line ALK inhibitors and is now also in first line. We present a retrospective observational study of the safety and efficacy of patients receiving Lorlatinib in second-line and beyond.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective observational study of ALK-positive patients who received Lorlatinib post-progression or intolerance to initial therapy at the Medical Oncology department. The patients who were started on Lorlatinib between January 2018 to December 2019 were included. The patients underwent routine blood and radiological evaluation every two to three months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 38 patients received Lorlatinib in the specified period. The median age was 48 years (range 23\u201368), with 53% of patients being male, 37% having comorbidities; the most common being hypertension and diabetes and 79% of patients were of ECOG-PS1. Twenty-two patients (58%) had received two prior TKIs. The most common sites of metastasis before starting Lorlatinib were brain (55%) and bone (53%). All patients except one received prior whole-brain radiotherapy with 4 receiving radiation twice. The median follow-up period was 49 months (95% CI: 46.4\u201351.6). Eighty-four percent showed disease control with median progression-free survival (PFS) and overall survival (OS) of 16 months (95% CI 5.4\u201326.6) and 22 months (95% CI 9.9\u201334.1) respectively. Twelve patients died without documented progression. Five out of twelve with documented progression had brain involvement while six had lung involvement. Twelve out of twenty-four patients who progressed received subsequent chemotherapy. The most common grade 3 and above toxicities were hypercholesterolemia and hypertriglyceridemia. Three (7.8%) patients required dose reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This real-world data confirms the efficacy of Lorlatinib in the second line and beyond with adverse effects matching that of registration studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s44276-024-00055-9","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:03:14Z","timestamp":1714521794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings"],"prefix":"10.1038","volume":"2","author":[{"given":"Amit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Janu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv Kumar","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Chougule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omshree","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/2278-330X.187571","volume":"5","author":"V Noronha","year":"2016","unstructured":"Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5:95\u2013103.","journal-title":"South Asian J Cancer"},{"key":"55_CR2","first-page":"100443","volume":"4","author":"A Kapoor","year":"2022","unstructured":"Kapoor A, Noronha V, Patil V, Menon N, Joshi A, Kumar A, et al. Clinical profile, practice pattern, and outcomes with first-line therapy in ALK-positive lung cancer: real-world data from resource-constrained settings. JTO Clin Res Rep. 2022;4:100443.","journal-title":"JTO Clin Res Rep"},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371:2167\u201377.","journal-title":"N. Engl. J. Med"},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non- small-cell lung cancer. N Engl J Med. 2017;377:829\u201338.","journal-title":"N Engl J Med"},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziusko R, Kim D-W, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056\u201364.","journal-title":"Ann Oncol"},{"key":"55_CR6","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","volume":"8","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Ou SH, Logan J, Borges LW, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013;8:1570\u20133.","journal-title":"J Thorac Oncol"},{"key":"55_CR7","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","volume":"363","author":"YL Choi","year":"2010","unstructured":"Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734\u20139.","journal-title":"N Engl J Med"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Kenudson MM, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4:120ra17.","journal-title":"Sci Transl Med"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, et al. Clinical management of adverse events associated with Lorlatinib. Oncologist. 2019;24:1103\u201310.","journal-title":"Oncologist"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)\u20107\u2010amino\u201012\u2010fluoro\u20102,10,16\u2010trimethyl\u201015\u2010oxo\u201010,15,16,17\u2010tetrahydro\u20102h\u20108,4\u2010(metheno)pyrazolo[4,3\u2010h][2,5,11]\u2010benzoxadiazacyclotetradecine\u20103\u2010carbonitrile (PF\u201006463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c\u2010ros oncogene 1 (ROS1) with preclinical brain exposure and broad\u2010spectrum potency against ALK\u2010resistant mutations. J Med Chem. 2014;57:4720\u201344.","journal-title":"J Med Chem"},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","volume":"36","author":"AH Schinkel","year":"1999","unstructured":"Schinkel AH. P\u2010glycoprotein, a gatekeeper in the blood\u2010brain barrier. Adv Drug Deliv Rev. 1999;36:179\u201394.","journal-title":"Adv Drug Deliv Rev"},{"key":"55_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. PF\u201006463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28:70\u201381.","journal-title":"Cancer Cell"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654\u201367.","journal-title":"Lancet Oncol"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.lungcan.2020.07.022","volume":"148","author":"N Peled","year":"2020","unstructured":"Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Flippova E, et al. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients. Lung Cancer. 2020;148:48\u201354.","journal-title":"Lung Cancer"},{"key":"55_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lungcan.2022.05.012","volume":"169","author":"RA Soo","year":"2022","unstructured":"Soo RA, Huat-Tan E, Hayashi H, Seto T, Lin CC, Ou SHI, et al. Efficacy and safety of Lorlatinib in Asian and Non-Asian patients with ALK-positive advanced non-small cell lung cancer: subgroup analysis of a global phase 2 trial. Lung Cancer. 2022;169:67\u201376.","journal-title":"Lung Cancer"},{"key":"55_CR16","doi-asserted-by":"publisher","first-page":"175883592098055","DOI":"10.1177\/1758835920980558","volume":"13","author":"N Frost","year":"2021","unstructured":"Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schafaer M, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021;13:1758835920980558.","journal-title":"Ther Adv Med Oncol"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2022.01.018","volume":"166","author":"S Baldacci","year":"2022","unstructured":"Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, et al. Lorlatinib for advanced anaplastic lymphoma kinase\u2013positive non\u2013small cell lung cancer: results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022;166:51\u20139.","journal-title":"Eur J Cancer"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jtho.2020.04.019","volume":"15","author":"VW Zhu","year":"2020","unstructured":"Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, et al. An international real-world analysis of efficacy and safety of lorlatinib through early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC. J Thorac Oncol. 2020;15:1484\u201396.","journal-title":"J Thorac Oncol"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/CAD.0000000000001107","volume":"32","author":"PH Lee","year":"2021","unstructured":"Lee PH, Chen KC, Hsu KH, Huang YH, Tseng JH, Yang TY, et al. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non\u2013small cell lung cancer patients. Anti-Cancer Drugs. 2021;32:1099\u2013104.","journal-title":"Anti-Cancer Drugs"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence\u2014what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"},{"key":"55_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"21903","DOI":"10.18632\/oncotarget.15746","volume":"8","author":"M Duruisseaux","year":"2017","unstructured":"Duruisseaux M, Besse B, Cadranel J, Perol M, Mennecier B, Bigay-Game L, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8:21903\u201317.","journal-title":"Oncotarget"},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR- mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108\u201311.","journal-title":"Lung Cancer"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8:714\u201329.","journal-title":"Cancer Discov"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/annonc\/mdt572","volume":"25","author":"SH Ou","year":"2014","unstructured":"Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25:415\u201322.","journal-title":"Ann Oncol"},{"key":"55_CR26","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118\u201333.","journal-title":"Cancer Discov"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00055-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:03:18Z","timestamp":1714521798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1038\/s44276-024-00055-9","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Dr. Noronha reports grants from Dr. Reddy\u2019s Laboratories \u00d0nc, grants from. Amgen, grants from Sanofi Aventis, outside the submitted work. Dr. Prabhash reports grants from Biocon Ltd, grants from Dr. Reddy\u2019s Laboratories Inc, grants from Fresenius Kabi India Pvt Ltd, grants from Alkem Laboratories, grants from Natco Pharma Ltd, grants from BDR Pharmaceutics Intl Pvt Ltd, grants from Roche Holding AG, outside the submitted work. None of the other authors have anything to declare that may be considered as potential competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The lung cancer audit is an Institutional Ethics Committee (IEC) approved observational protocol and is registered with the Clinical Trials Registry India (registration number: CTRI\/2013\/01\/003335). The study was conducted according to ethical guidelines established by the Declaration of Helsinki and other guidelines like Good Clinical Practice Guidelines and those established by the Indian Council of Medical Research (ICMR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"35"}}